- Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
- Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
- Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
- Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
- Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
- Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
- Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
- Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
- Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
- Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
More ▼
Key statistics
As of last trade, Nexalin Technology Inc (NXL:NAQ) traded at 1.11, 339.08% above the 52 week low of 0.2528 set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.11 |
---|---|
High | 1.19 |
Low | 1.06 |
Bid | 1.06 |
Offer | 1.11 |
Previous close | 1.15 |
Average volume | 36.26k |
---|---|
Shares outstanding | 7.44m |
Free float | 5.73m |
P/E (TTM) | -- |
Market cap | 8.55m USD |
EPS (TTM) | -0.6676 USD |
Data delayed at least 15 minutes, as of May 23 2024 17:42 BST.
More ▼